Milestone strengthens the company’s leadership in advanced IOL innovationFINEVISION HP, with millions of implantations worldwide, will now be available to U.S. patientsProprietary design features anchor the launch of BVI’s expanded U.S. IOL portfolio WALTHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- BVI, a global leader in ophthalmic device innovation, today announced that the U.S. Food and Drug Administration (FDA) has approved its FINEVISION HP trifocal intraocular lens (IOL). This milestone reinforces BV ...

Core Viewpoint - Johnson and Johnson reported strong third-quarter earnings, exceeding expectations, and announced plans to spin off its orthopedics business within the next two years, indicating a strategic shift towards accelerated growth in its core areas [1][4][12]. Financial Performance - The company achieved a revenue growth of 5.4% in the quarter, with significant contributions from its pharmaceutical segment, which grew 16% when excluding the impact of Stellara [3][5]. - Johnson and Johnson raised its full-year revenue guidance while maintaining its elevated EPS guidance, demonstrating confidence in its growth trajectory [4]. Business Segments - The pharmaceutical business saw 11 brands growing at double-digit rates, with TFIA being a standout product that grew by 40% [5]. - The met business experienced a sequential growth of 57%, and the cardiovascular segment grew by 12%, highlighting the success of recent acquisitions [6]. Spin-off of Orthopedics Business - The decision to spin off the orthopedics business is aimed at allowing both Johnson and Johnson and the new entity to focus on breakthrough innovations and improve competitive positioning in a $50 billion market [12][14]. - The orthopedics segment accounts for approximately 10% of the company's revenue, which is $9.2 billion out of a total annual revenue of $93 billion [14]. Market Performance - Johnson and Johnson's stock has seen significant appreciation, up 18% over the past year and 32% year-to-date, reflecting investor confidence in the company's growth prospects [15][16]. Pipeline and Future Growth - The company has a robust pipeline, including a new therapy for localized bladder cancer and an oral peptide for autoimmune diseases, which are expected to drive future growth [17][18][19]. - The surgical robotic system Otava is also in development, with plans to file with the FDA in the coming year, further contributing to the growth strategy [19].

Johnson & Johnson said it plans to separate its artificial hip and knee business into a stand-alone company to be called DePuy Synthes https://t.co/esl7QarjXl ...

Core Insights - Abbott Laboratories is expected to report third-quarter earnings on October 15, 2025, with an anticipated EPS of $1.30, reflecting a 7.4% increase year-over-year, and projected revenue of $11.4 billion, up from $10.63 billion a year ago [1][6] Financial Performance - The anticipated EPS of $1.30 represents an 8.3% year-over-year growth, indicating strong performance despite a recent stock decline of 0.6%, closing at $132.57 [2] - Abbott's financial metrics include a price-to-earnings (P/E) ratio of approximately 16.36 and a price-to-sales ratio of about 5.30, suggesting a favorable market valuation [4] - The company's debt-to-equity ratio stands at 0.27, indicating a relatively low level of debt, while a current ratio of 1.82 reflects strong liquidity to cover short-term liabilities [4] Strategic Focus - Abbott's strategic emphasis on expanding its diabetes care solutions is identified as a key driver for future growth, transitioning from devices to comprehensive, data-driven care solutions [3][6] - This strategic move is expected to enhance Abbott's competitive edge and contribute to its long-term success in the healthcare industry [3] Analyst Insights - The consensus earnings estimate for Abbott has been slightly adjusted downward by 0.1% over the past month, reflecting analysts' reassessment of initial projections [5] - This adjustment could influence investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock price performance [5]

Johnson & Johnson raised its full-year sales outlook as it posted gains in both its prescription-drug and medical-device businesses in the latest quarter. ...

Johnson & Johnson on Tuesday said it plans to separate its orthopedics business into a standalone company named DePuy Synthes within the next 18 to 24 months, marking its second major spinoff since 20... ...

Overall financial results Regional sales results Segment sales results Third-Quarter 2025 segment commentary: Operational sales* reflected below excludes the impact of translational currency. Innovative Medicine Innovative Medicine worldwide operational sales grew 5.3%*, with net acquisitions and divestitures positively impacting growth by 1.6% due to CAPLYTA. Growth was primarily driven by DARZALEX, CARVYKTI, ERLEADA and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, and SP ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Johnson & Johnson said Tuesday that it plans to spin out its orthopedics business, creating a standalone company that would compete with firms like Stryker and Zimmer Biomet. The healthcare giant said the decision is intended to focus its medtech unit on higher-growth and higher-margin markets. The spinout, which will be called DePuy Synthes, is expected to happen in ...

Electromed, Inc. to Participate in LD Micro Main Event XIXManagement will present Monday, October 20, 2025 at 10:00 am PTOctober 13, 2025 4:30 PM EDT | Source: LD MicroNew Prague, Minnesota--(Newsfile Corp. - October 13, 2025) - Electromed, Inc. (NYSE American: ELMD) ("Electromed" or the "Company"), a leader in innovative airway clearance technologies, today announced that Company management will participate in the LD Micro Main Event XIX Conference being held October 19-21, 2025 in San Diego. ...

Key Takeaways INSP reported positive Inspire V data with enhanced safety and better patient adherence.INSP's trials showed 20% shorter surgical times and superior AHI improvement versus Inspire IV.INSP's U.S. release confirmed efficient implantation, stable therapy use and no serious adverse events. Inspire Medical Systems (INSP) recently unveiled promising clinical data from its Inspire V system at the ISSS and AAO-HNS meetings, showcasing strong safety, enhanced respiratory sensing and improved patient ad ...